Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 2
1966 1
1967 1
1969 1
1971 1
1974 1
1975 4
1976 3
1977 9
1978 4
1979 10
1981 5
1982 13
1983 15
1984 17
1985 7
1986 10
1987 8
1988 10
1989 9
1990 2
1991 9
1992 7
1993 7
1994 14
1995 19
1996 18
1997 17
1998 18
1999 19
2000 18
2001 20
2002 13
2003 17
2004 23
2005 17
2006 16
2007 17
2008 15
2009 15
2010 22
2011 30
2012 25
2013 21
2014 19
2015 29
2016 21
2017 10
2018 9
2019 9
2020 5
2021 4
2022 3
2023 2
2024 5
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

606 results

Results by year

Filters applied: . Clear all
Page 1
Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data.
Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, Jafar T, Jassal SK, Landman GW, Muntner P, Roderick P, Sairenchi T, Schöttker B, Shankar A, Shlipak M, Tonelli M, Townend J, van Zuilen A, Yamagishi K, Yamashita K, Gansevoort R, Sarnak M, Warnock DG, Woodward M, Ärnlöv J; CKD Prognosis Consortium. Matsushita K, et al. Among authors: warnock dg. Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-25. doi: 10.1016/S2213-8587(15)00040-6. Epub 2015 May 28. Lancet Diabetes Endocrinol. 2015. PMID: 26028594 Free PMC article.
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Wallace EL, Goker-Alpan O, Wilcox WR, Holida M, Bernat J, Longo N, Linhart A, Hughes DA, Hopkin RJ, Tøndel C, Langeveld M, Giraldo P, Pisani A, Germain DP, Mehta A, Deegan PB, Molnar MJ, Ortiz D, Jovanovic A, Muriello M, Barshop BA, Kimonis V, Vujkovac B, Nowak A, Geberhiwot T, Kantola I, Knoll J, Waldek S, Nedd K, Karaa A, Brill-Almon E, Alon S, Chertkoff R, Rocco R, Sakov A, Warnock DG. Wallace EL, et al. Among authors: warnock dg. J Med Genet. 2024 May 21;61(6):520-530. doi: 10.1136/jmg-2023-109445. J Med Genet. 2024. PMID: 37940383 Free PMC article. Clinical Trial.
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ; Fabry Disease Clinical Trial Study Group. Banikazemi M, et al. Among authors: warnock dg. Ann Intern Med. 2007 Jan 16;146(2):77-86. doi: 10.7326/0003-4819-146-2-200701160-00148. Epub 2006 Dec 18. Ann Intern Med. 2007. PMID: 17179052 Free article. Clinical Trial.
Controversies in orthopaedic oncology.
Jeys LM, Thorkildsen J, Kurisunkal V, Puri A, Ruggieri P, Houdek MT, Boyle RA, Ebeid W, Botello E, Morris GV; BOOM Consensus Scientific Committee; Laitinen MK; BOOM Consensus Scientific Committee; Abudu A, Ae K, Agarwal M, Ajit Singh V, Akiyama T, Albergo JI, Alexander J, Alpan B, Aoude A, Asavamongkolkul A, Aston W, Baad-Hansen T, Balach T, Benevenia J, Bergh P, Bernthal N, Binitie O, Boffano M, Bramer J, Branford White H, Brennan B, Cabrolier J, Calvo Haro JA, Campanacci DA, Cardoso R, Carey Smith R, Casales Fresnga N, Casanova JM, Ceballos O, Chan CM, Chung YG, Clara-Altamirano MA, Cribb G, Dadia S, Dammerer D, de Vaal M, Delgado Obando J, Deo S, Di Bella C, Donati DM, Endo M, Eralp L, Erol B, Evans S, Eward W, Fiorenza F, Freitas J, Funovics PT, Galli Serra M, Ghert M, Ghosh K, Gomez Mier LC, Gomez Vallejo J, Griffin A, Gulia A, Guzman M, Hardes J, Healey J, Hernandez A, Hesla A, Hongsaprabhas C, Hornicek F, Hosking K, Iwata S, Jagiello J, Johnson L, Johnston A, Joo M, Jutte P, Kapanci B, Khan Z, Kobayashi H, Kollender Y, Koob S, Kotrych D, Le Nail LR, Legosz P, Lehner B, Leithner A, Lewis V, Lin P, Linares F, Lozano Calderon S, Mahendra A, Mahyudin F, Mascard E, Mattei JC, Mc… See abstract for full author list ➔ Jeys LM, et al. Among authors: warnock d. Bone Joint J. 2024 May 1;106-B(5):425-429. doi: 10.1302/0301-620X.106B5.BJJ-2023-1381. Bone Joint J. 2024. PMID: 38689572
A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.
Holida M, Linhart A, Pisani A, Longo N, Eyskens F, Goker-Alpan O, Wallace E, Deegan P, Tøndel C, Feldt-Rasmussen U, Hughes D, Sakov A, Rocco R, Almon EB, Alon S, Chertkoff R, Warnock DG, Waldek S, Wilcox WR, Bernat JA. Holida M, et al. Among authors: warnock dg. J Inherit Metab Dis. 2025 Jan;48(1):e12795. doi: 10.1002/jimd.12795. Epub 2024 Oct 9. J Inherit Metab Dis. 2025. PMID: 39381863 Free PMC article. Clinical Trial.
Fabry disease: dose matters.
Warnock DG, Mauer M. Warnock DG, et al. J Am Soc Nephrol. 2014 Apr;25(4):653-5. doi: 10.1681/ASN.2013121322. Epub 2014 Feb 20. J Am Soc Nephrol. 2014. PMID: 24556355 Free PMC article. No abstract available.
Hypertension.
Warnock DG, Textor SC. Warnock DG, et al. Am J Kidney Dis. 2004 Aug;44(2):369-75. doi: 10.1053/j.ajkd.2004.06.002. Am J Kidney Dis. 2004. PMID: 15264197 Review. No abstract available.
606 results